Sanofi has agreed to buy the US medical device company Pluromed in order to strengthen the biosurgery portfolio it gained via its takeover of Genzyme in 2011. With the acquisition, Sanofi will gain Pluromed’s biocompatible reverse thermosensitive polymer technology, Rapid Transition Polymers™, and LeGoo® gel, which was approved by the US FDA in September 2011 and which provides temporary blood vessel occlusion during surgery